RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00632463|
Recruitment Status : Completed
First Posted : March 10, 2008
Results First Posted : April 24, 2013
Last Update Posted : April 24, 2013
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Upper Respiratory Tract Infection Lower Respiratory Tract Infection||Biological: RI-001||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness|
|Study Start Date :||February 2008|
|Actual Primary Completion Date :||May 2010|
|Actual Study Completion Date :||May 2010|
Dose regimen 1
Dose regimen 2
Placebo Comparator: 3
- Circulating RI-001 Titer [ Time Frame: Study day 18 ]The primary endpoint of this study was the mean fold titer increase from baseline to Day 18 in circulating serum anti-RSV neutralizing antibody following treatment with RI-001.
- Incidence of RSV Progression From Symptomatic Upper Respiratory Tract Infection to Lower Respiratory Tract Infection. [ Time Frame: Study day 33 ]
- The Number of Patients Achieving at Least a 4-fold Increase in Serum RSV Neutralizing Antibody Titers [ Time Frame: 18 Days ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||2 Years to 65 Years (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- An IEC/IRB approved written informed consent signed and dated by the patient or by parent(s) or a legally acceptable representative. The consent form or a specific assent form, where required, will be signed and dated by minors.
- Documented Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT), Pulmonary/Cardiac Transplant, Pulmonary Transplant or Liver Transplant within the 2 years prior to randomization to the study drug.
- Male/Female patients age: (Pediatric) ≥2 years and <16 years at the time of informed consent.
- Male/Female patients age: (Adult) ≥ 16 years and ≤ 65 years at the time of informed consent.
- Patient must have an URTI as defined by Respiratory Assessment Score (RAS)=1.
- Patients must be actively taking at least one immunosuppressive agent.
- Patients must have a positive RSV RT-PCR at the time of the randomization procedures.
- Female patients must be of non-childbearing potential or have a negative pregnancy test prior to study start and be deemed not at risk of becoming pregnant by adherence to a reliable contraceptive method for the duration of the study. Females of non-childbearing potential are defined as women who have had a hysterectomy, bilateral oophorectomy, tubal ligation or who have been post-menopausal for at least two years, or are considered to be sterile due to recent chemotherapy.
- Female patients who are not breast-feeding.
- Patient/legally acceptable representative considered as reliable and capable of adhering to the protocol (e.g. able to understand and complete diaries and questionnaires), visit schedules or treatment regimen according to the judgment of the Investigator.
- Documented RSV lower respiratory tract infection (respiratory assessment score is greater than 1) as determined by the site investigators or research staff.
- Requirement for mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure or other mechanical respiratory or cardiac support
- Unstable respiratory status so severe that survival is not expected for longer than 6 months.
- End organ dysfunction resulting in anticipated survival of less than 6 months.
- Known to be HIV positive.
- Administration of any RSV specific products, including palivizumab (Synagis®) in the 3 months prior to randomization procedures.
- Previous, current, or planned administration of an investigational RSV vaccine.
- Known hypersensitivity to immunoglobulin.
- Known Immunoglobulin (IgA) deficiency
- Known renal impairment requiring any form of dialysis (HD, PD, CRRT).
- Known hemodynamically significant congenital heart disease.
- Previous poor compliance with visit schedules.
- Severe medical, neurological or psychiatric disorders or laboratory values which may have an impact on the safety of the patient.
- Concurrent participation in other investigational drug product studies; any exception must be approved by the ADMA Biologics Medical Director.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00632463
|Principal Investigator:||Upton Allen, MBBS||Division of Infectious Diseases, Hospital for Sick Children, Toronto, Ontario, Canada|
|Responsible Party:||ADMA Biologics, Inc.|
|Other Study ID Numbers:||
|First Posted:||March 10, 2008 Key Record Dates|
|Results First Posted:||April 24, 2013|
|Last Update Posted:||April 24, 2013|
|Last Verified:||March 2013|
Respiratory Tract Infections
Respiratory Tract Diseases